In the present study, we developed a self-assembled biodegradable
polyglutamic acid (
PGA)-based formulation of
amphotericin B (AmB) and evaluated its in vitro antifungal potential against Candida albicans. The AmB-loaded
PGA nanoparticles were prepared in-house and had a mean size dimension of around 98±2 nm with a zeta potential of -35.2±7.3 mV. Spectroscopic studies revealed that the
drug predominantly acquires an aggregated form inside the formulation with an aggregation ratio above 2. The
PGA-based AmB formulation was shown to be highly stable in
phosphate-buffered saline as well as in serum (only 10%-20% of the
drug was released after 10 days). The AmB-
PGA nanoparticles were less toxic to red blood cells (<15% lysis at an AmB concentration of 100 μg/mL after 24 hours) when compared with
Fungizone(®), a commercial antifungal product. An MTT assay showed that the viability of mammalian cells (KB and RAW 264.7) was negligibly affected at AmB concentrations as high as 200 μg/mL. Histopathological examination of mouse kidney revealed no signs of tissue
necrosis. The AmB-
PGA formulation showed potent antimicrobial activity similar to that of
Fungizone against C. albicans. Interestingly, AmB-bearing
PGA nanoparticles were found to inhibit biofilm formation to a considerable extent. In summary, AmB-
PGA nanoparticles showed highly attenuated toxicity when compared with
Fungizone, while retaining equivalent active antifungal properties. This study indicates that the AmB-
PGA preparation could be a promising treatment for various
fungal infections.